Society Logo
ME/CFS Australia Ltd
Please click here to donate ME/CFS South Australia Inc

Registered Charity 3104


Mailing address:

PO Box 322,
Modbury North,
South Australia 5092

1300 128 339

Office Hours:
Monday - Friday,
10am - 4pm

ME/CFS South Australia Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.


ME/CFS South Australia Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.

Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.

Become a Member
DOCX Application Form (Word, 198 KB)
Why become a member?

Pfizer's once-daily Lyrica met goal of trial in Fibromyalgia

Wednesday 21 November 2012


From Reuters:


Pfizer headquartersPfizer's once-daily Lyrica met goal of trial in fibromyalgia

Mon Nov 19, 2012 8:58am EST

(Reuters) - Pfizer Inc said on Monday a late-stage trial of a once-daily version of its drug Lyrica in patients with fibromyalgia, a pain condition affecting more than 5 million Americans, met its main goal.

Patients taking once-daily Lyrica, also known as pregabalin, went for a significantly longer period of time before feeling pain compared with patients who took a placebo.

The study is the second of three late-stage trials testing a controlled-release version of the drug, which is currently given several times a day.

A trial of the controlled-release version of the drug in patients with certain types of seizures did not meet its main goal, Pfizer said.

The company is also studying the drug in patients with neuralgia.

(Reporting By Toni Clarke; editing by John Wallace)


The above originally appeared here.


Arrow right

More Fibromyalgia News



blog comments powered by Disqus
Previous Previous Page